Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

Yair Lotan, Shahrokh F. Shariat, Bernd J. Schmitz-Dräger, Marta Sanchez-Carbayo, Feliksas Jankevicius, Marco Racioppi, Sarah J P Minner, Brigitte Stöhr, Pier Francesco Bassi, H. Barton Grossman

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. Cystoscopy is the main tool in detection and surveillance of bladder cancer but is invasive and can miss some cancers. Cytology is frequently utilized but suffers from a poor sensitivity. There are several commercially available urine-based tumor markers currently available but their use is not recommended by guideline panels. Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. The added benefit of these markers and other commercially available markers (e.g. Ucyt+, BTA stat) has not been well investigated though it appears these markers are insufficiently sensitive to replace cystoscopy. Additional studies are needed to determine the clinical scenarios where bladder markers are best utilized (screening, surveillance, early detection, evaluating cytologic atypia) and what impact they should have on clinical decision making. Furthermore, a variety of issues and barriers can affect the movement of clinical tests from research to clinical practice. This article addresses some of the challenges facing research and medical communities in the delivery and integration of markers for bladder cancer diagnosis. Moreover, we attempt to outline criteria for the clinical utility of new bladder cancer diagnostic markers.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Urinary Bladder Neoplasms
Cystoscopy
Hematuria
Tumor Biomarkers
Cell Biology
Biomedical Research
Urinary Bladder
Urine
Guidelines
Recurrence
Clinical Decision-Making
Research
Neoplasms

Keywords

  • Bladder cancer
  • Urine based tumor markers

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this

Lotan, Y., Shariat, S. F., Schmitz-Dräger, B. J., Sanchez-Carbayo, M., Jankevicius, F., Racioppi, M., ... Grossman, H. B. (2010). Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 28(4), 441-448. https://doi.org/10.1016/j.urolonc.2009.11.004

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. / Lotan, Yair; Shariat, Shahrokh F.; Schmitz-Dräger, Bernd J.; Sanchez-Carbayo, Marta; Jankevicius, Feliksas; Racioppi, Marco; Minner, Sarah J P; Stöhr, Brigitte; Bassi, Pier Francesco; Grossman, H. Barton.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 4, 2010, p. 441-448.

Research output: Contribution to journalArticle

Lotan, Y, Shariat, SF, Schmitz-Dräger, BJ, Sanchez-Carbayo, M, Jankevicius, F, Racioppi, M, Minner, SJP, Stöhr, B, Bassi, PF & Grossman, HB 2010, 'Considerations on implementing diagnostic markers into clinical decision making in bladder cancer', Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 4, pp. 441-448. https://doi.org/10.1016/j.urolonc.2009.11.004
Lotan, Yair ; Shariat, Shahrokh F. ; Schmitz-Dräger, Bernd J. ; Sanchez-Carbayo, Marta ; Jankevicius, Feliksas ; Racioppi, Marco ; Minner, Sarah J P ; Stöhr, Brigitte ; Bassi, Pier Francesco ; Grossman, H. Barton. / Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. In: Urologic Oncology: Seminars and Original Investigations. 2010 ; Vol. 28, No. 4. pp. 441-448.
@article{32d340fbf2214e658d3876a2775bf4d5,
title = "Considerations on implementing diagnostic markers into clinical decision making in bladder cancer",
abstract = "Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. Cystoscopy is the main tool in detection and surveillance of bladder cancer but is invasive and can miss some cancers. Cytology is frequently utilized but suffers from a poor sensitivity. There are several commercially available urine-based tumor markers currently available but their use is not recommended by guideline panels. Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. The added benefit of these markers and other commercially available markers (e.g. Ucyt+, BTA stat) has not been well investigated though it appears these markers are insufficiently sensitive to replace cystoscopy. Additional studies are needed to determine the clinical scenarios where bladder markers are best utilized (screening, surveillance, early detection, evaluating cytologic atypia) and what impact they should have on clinical decision making. Furthermore, a variety of issues and barriers can affect the movement of clinical tests from research to clinical practice. This article addresses some of the challenges facing research and medical communities in the delivery and integration of markers for bladder cancer diagnosis. Moreover, we attempt to outline criteria for the clinical utility of new bladder cancer diagnostic markers.",
keywords = "Bladder cancer, Urine based tumor markers",
author = "Yair Lotan and Shariat, {Shahrokh F.} and Schmitz-Dr{\"a}ger, {Bernd J.} and Marta Sanchez-Carbayo and Feliksas Jankevicius and Marco Racioppi and Minner, {Sarah J P} and Brigitte St{\"o}hr and Bassi, {Pier Francesco} and Grossman, {H. Barton}",
year = "2010",
doi = "10.1016/j.urolonc.2009.11.004",
language = "English (US)",
volume = "28",
pages = "441--448",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

AU - Lotan, Yair

AU - Shariat, Shahrokh F.

AU - Schmitz-Dräger, Bernd J.

AU - Sanchez-Carbayo, Marta

AU - Jankevicius, Feliksas

AU - Racioppi, Marco

AU - Minner, Sarah J P

AU - Stöhr, Brigitte

AU - Bassi, Pier Francesco

AU - Grossman, H. Barton

PY - 2010

Y1 - 2010

N2 - Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. Cystoscopy is the main tool in detection and surveillance of bladder cancer but is invasive and can miss some cancers. Cytology is frequently utilized but suffers from a poor sensitivity. There are several commercially available urine-based tumor markers currently available but their use is not recommended by guideline panels. Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. The added benefit of these markers and other commercially available markers (e.g. Ucyt+, BTA stat) has not been well investigated though it appears these markers are insufficiently sensitive to replace cystoscopy. Additional studies are needed to determine the clinical scenarios where bladder markers are best utilized (screening, surveillance, early detection, evaluating cytologic atypia) and what impact they should have on clinical decision making. Furthermore, a variety of issues and barriers can affect the movement of clinical tests from research to clinical practice. This article addresses some of the challenges facing research and medical communities in the delivery and integration of markers for bladder cancer diagnosis. Moreover, we attempt to outline criteria for the clinical utility of new bladder cancer diagnostic markers.

AB - Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. Cystoscopy is the main tool in detection and surveillance of bladder cancer but is invasive and can miss some cancers. Cytology is frequently utilized but suffers from a poor sensitivity. There are several commercially available urine-based tumor markers currently available but their use is not recommended by guideline panels. Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. The added benefit of these markers and other commercially available markers (e.g. Ucyt+, BTA stat) has not been well investigated though it appears these markers are insufficiently sensitive to replace cystoscopy. Additional studies are needed to determine the clinical scenarios where bladder markers are best utilized (screening, surveillance, early detection, evaluating cytologic atypia) and what impact they should have on clinical decision making. Furthermore, a variety of issues and barriers can affect the movement of clinical tests from research to clinical practice. This article addresses some of the challenges facing research and medical communities in the delivery and integration of markers for bladder cancer diagnosis. Moreover, we attempt to outline criteria for the clinical utility of new bladder cancer diagnostic markers.

KW - Bladder cancer

KW - Urine based tumor markers

UR - http://www.scopus.com/inward/record.url?scp=77953850928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953850928&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.11.004

DO - 10.1016/j.urolonc.2009.11.004

M3 - Article

C2 - 20610281

AN - SCOPUS:77953850928

VL - 28

SP - 441

EP - 448

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 4

ER -